About: Multiple sclerosis drug pipeline

An Entity of Type: Thing, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate. Pharmaceuticals already on the market, such as Vitamin D do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such drugs implies neither efficacy nor lack of efficacy.

Property Value
dbo:abstract
  • There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate. Pharmaceuticals already on the market, such as Vitamin D do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such drugs implies neither efficacy nor lack of efficacy. In general, novel pharmaceuticals cannot enter a market without government approval; standards and political influences vary. (en)
dbo:wikiPageID
  • 51173038 (xsd:integer)
dbo:wikiPageLength
  • 82739 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1080555924 (xsd:integer)
dbo:wikiPageWikiLink
dbp:wikiPageUsesTemplate
dcterms:subject
rdfs:comment
  • There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate. Pharmaceuticals already on the market, such as Vitamin D do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such drugs implies neither efficacy nor lack of efficacy. (en)
rdfs:label
  • Multiple sclerosis drug pipeline (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is rdfs:seeAlso of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License